Mary Wilson
New member
October 28, 2020
DOI: 10.1056/NEJMp2030600
Sam Halabi, J.D., Andrew Heinrich, J.D., and Saad B. Omer, M.B., B.S., Ph.D., M.P.H.
The Covid-19 pandemic has triggered a global vaccine race. As of September 27, 2020, there were more than 200 vaccine candidates in preclinical and clinical development, including 11 in phase 3 trials. Wealthy governments that have invested in vaccine candidates have made bilateral agreements with developers that could result in vaccine doses being reserved for the highest-income countries — a phenomenon known as “vaccine nationalism” — potentially leaving people in poor countries vulnerable to Covid-19.
... Equally important is offering companies protection against potentially substantial liability should Covid-19 vaccines cause real or perceived injuries to recipients. Manufacturers won’t agree to procurement contracts or ship vaccine without liability protection. According to an AstraZeneca executive, for example, in the company’s bilateral contracts, it has been granted protection against legal claims arising from the use of its vaccine products, since it “cannot take the risk” of liability.[SUP]1
https://www.nejm.org/doi/full/10.1056/NEJMp2030600?query=featured_home[/SUP]
DOI: 10.1056/NEJMp2030600
Sam Halabi, J.D., Andrew Heinrich, J.D., and Saad B. Omer, M.B., B.S., Ph.D., M.P.H.
The Covid-19 pandemic has triggered a global vaccine race. As of September 27, 2020, there were more than 200 vaccine candidates in preclinical and clinical development, including 11 in phase 3 trials. Wealthy governments that have invested in vaccine candidates have made bilateral agreements with developers that could result in vaccine doses being reserved for the highest-income countries — a phenomenon known as “vaccine nationalism” — potentially leaving people in poor countries vulnerable to Covid-19.
... Equally important is offering companies protection against potentially substantial liability should Covid-19 vaccines cause real or perceived injuries to recipients. Manufacturers won’t agree to procurement contracts or ship vaccine without liability protection. According to an AstraZeneca executive, for example, in the company’s bilateral contracts, it has been granted protection against legal claims arising from the use of its vaccine products, since it “cannot take the risk” of liability.[SUP]1
https://www.nejm.org/doi/full/10.1056/NEJMp2030600?query=featured_home[/SUP]